Large holder of Osir releases prelim year-end report
Earlier today a fellow poster noted a burst of buying in NEW VENTURE TEC which holds over 4 million shares of OSIR. The following release today, from Switzerland may have something to do with that.
For further information:
Tel: 041 740 26 26
Result expectation for the fiscal year 2012/2013
ended September 30, 2013
New Venturetec ended its fiscal year 2012/13 on September 30,2013. Based on the current valuations of the portfolio companies New Venturetec expects a consolidated net gain of approximately USD 16,500,000
or USD 3.30 per share. The main reason for the gain is the increase of the traded share price of Osiris Therapeutics from USD 11.05 per share to USD 16.64 per share in the reporting period.
The estimated numbers could change materially during the course of the end year valuation process of
the portfolio, which will be done in the coming weeks. The final annual financials, together
with the annual report of New Venturetec 2012/13 will be published on November 13, 2013.
New Venturetec did not give any guidance on its performance for the fiscal year 2012/13
and has never done so in the past. New Venturetec is a publicly traded Swiss investment company (SIX:NEV) which invests directly inventure capital companiesin the area of biotechnology and technology
in the USA.